MiRNA-based Therapeutics for Lung Cancer

Title:MiRNA-based Therapeutics for Lung Cancer

Volume: 23 Issue: 39

Author(s): Miaowei Wu*, Guosheng Wang*, Wei Tian, Yongchuan Deng and Yibing Xu

Affiliation:

• Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Surg Oncol, 88 Jiefang Rd, Hangzhou 310009, Zhejiang,China

• Zhejiang Univ, Sch Med, Inst Translat Med, Hangzhou 310029, Zhejiang,China

Keywords: miRNA, oncogene, tumor suppressor, drug resistance, lung cancer, therapy.

Abstract: Background: miRNA, a small non-coding RNA molecule containing about 22 nucleotides, functions in RNA silencing and post-transcriptional regulation of gene expression. With these qualities, miRNAs modulate multiple signaling pathways involved in cancer development, such as cellular proliferation, apoptosis, and migration.

Methods: The goal of this review is to discuss possible miRNAs-based therapeutic strategies, through defining performance of miRNAs in carcinogenesis, in particular in lung cancer.

Results: miRNA, a non-coding RNA, is divided into two main types: tumor suppressor miRNAs and oncogenic miRNAs. In addition, special processed miRNAs can be an assistant therapeutic tool.

Conclusion: In order to develope antitumor therapy, miRNAs-based therapeutic strategies are worth of deeper studies. In this process, the stability, effectiveness, and side effects should be considered.

Cite this article as:

Wu Miaowei *, Wang Guosheng *, Tian Wei , Deng Yongchuan and Xu Yibing , MiRNA-based Therapeutics for Lung Cancer, Current Pharmaceutical Design 2017; 23 (39) . https://dx.doi.org/10.2174/1381612823666170714151715